NASDAQ:LMNX - Luminex Stock Price, Price Target & More

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Friday, May 18th. Stockholders of record on Friday, June 22nd will be given a dividend of $0.06 per share on Friday, July 13th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, June 21st. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, May, 7th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.08. The medical instruments supplier earned $82.60 million during the quarter, compared to analyst estimates of $80.52 million. Luminex had a return on equity of 8.07% and a net margin of 10.60%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 earnings per share. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Luminex.

4 brokerages have issued 1 year price objectives for Luminex's shares. Their predictions range from $21.00 to $26.00. On average, they expect Luminex's share price to reach $23.00 in the next twelve months. View Analyst Ratings for Luminex.

Luminex saw a drop in short interest in the month of May. As of May 31st, there was short interest totalling 1,741,856 shares, a drop of 44.1% from the May 15th total of 3,113,587 shares. Based on an average daily volume of 522,399 shares, the days-to-cover ratio is currently 3.3 days. Approximately 4.2% of the shares of the company are short sold. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR), Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT) and Cardiovascular Systems (CSII).

News coverage about LMNX stock has been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Luminex earned a news impact score of 0.10 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Luminex's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.95%), Dimensional Fund Advisors LP (4.39%), Neuberger Berman Group LLC (2.60%), Millennium Management LLC (2.34%), Investment Management of Virginia LLC (2.21%) and Northern Trust Corp (2.15%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Neuberger Berman Group LLC, Alambic Investment Management L.P., Thomson Horstmann & Bryant Inc., Elk Creek Partners LLC, Blair William & Co. IL, American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Insider Buying and Selling for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Hancock Holding Co., DAFNA Capital Management LLC, Dimensional Fund Advisors LP, Millennium Management LLC, Tamarack Advisers LP, Federated Investors Inc. PA, BlackRock Inc. and Great Lakes Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $30.88.

Luminex has a market capitalization of $1.37 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]